VERTEX PHARMACEUTICALS INC / MA Marketable Securities (Current)
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Marketable Securities (Current) of $1.71 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-04
- 2026-06-30: Marketable Securities, Current $1.71B.
- 2026-03-31: Marketable Securities, Current $1.75B.
- 2025-12-31: Marketable Securities, Current $1.52B.
- 2025-09-30: Marketable Securities, Current $1.35B.
| Period end | Marketable Securities, Current | Marketable Securities, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.71B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.75B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.52B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $1.35B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.41B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $1.53B 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $1.55B 10-K · filed 2026-02-13 | |
| 2024-09-30 | $1.29B 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $1.22B 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $1.01B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $849.20M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $818.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.09B 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $1.12B 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $274.50M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $599.20M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $551.20M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $638.00M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $729.90M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $685.19M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $644.32M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $619.64M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $670.70M 10-K · filed 2022-02-09 | $670.71M 10-K · filed 2021-02-11 |
| 2020-09-30 | $792.97M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $619.44M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $596.98M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $698.97M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $598.39M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $656.54M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $584.15M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $518.11M 10-K · filed 2020-02-13 | |
| 2018-09-30 | $577.58M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $622.40M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $481.12M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $423.25M 10-Q · filed 2018-10-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |